Prospects of systemic enzyme therapy for treatment of male immune infertility

Abstract

The study objective is to evaluate the effectiveness and safety of systemic enzyme therapy drugs (Wobenzym, Phlogenzym) and the natural complex of multi-component dietary supplement Spermstrong in the treatment of immune infertility.Materials and methods. Sixty-four men with immune infertility, high levels of antisperm antibodies (ASA) in ejaculate, serum and reproductive disorders were examined. All patients were divided into 2 groups. For 8 weeks, 32 patients in the group 1 received systemic enzyme therapy drugs in combination with a natural complex of multi-component dietary supplement Spermstrong (combined therapy), and 32 patients of the group 2 received only Spermstrong (monotherapy), and their comparative assessment was carried out. Immediate results of treatment were evaluated 4 weeks later and remote 8 weeks after treatment.Results. Increased ejaculate volume was observed in patients receiving combination therapy and Spermstrong only: by 19.0 and 10.0 %, respectively, after 4 weeks of treatment and by 42.9 and 15.0 % after 8 weeks. Mean sperm count increased only in patients receiving combination therapy (by 55.4 % after 8 weeks of treatment, p <0.05). Sperm motility increased more after combination therapy (by 11.9 and 129.8 % after 4 and 8 weeks, respectively). Decrease in abnormal spermatozoa was slightly faster for combination treatment compared to Spermstrong monotherapy: after 4 weeks by 12.2 and 0.3 %, respectively, after 8 weeks by 24.8 and 6.5 %. The level of ASA IgG in the ejaculate decreased by 26.3 and 59.0 % after 4 and 8 weeks of combination treatment, and by 3.4 and 13.2 % after Spermstrong monotherapy. Serum level of ASA IgG/IgM significantly decreased only in patients receiving combination therapy (by 36.4 and 76.5 % after 4 and 8 weeks, respectively, p <0.05). No adverse effects were observed in patients in both treatment groups.Conclusion. The results confirm that the use of combination therapy with Wobenzym, Phlogenzym and Spermstrong statistically significantly reduced ASA levels and increased the effectiveness of treatment.The authors declare no conflict of interest.All patients gave written informed consent to participate in the study.

Keywords

• male immune infertility
• antisperm antibodies
• systemic enzyme therapy
• wobenzym
• phlogenzym
• antioxidant
• spermstrong
• treatment